ABSTRACT
Although TRPV1 receptors play an essential role in the adverse effects on the airways following captopril treatment, there is no available evidence of their involvement in treatment regimens involving repeated doses of captopril. Comparing the difference in these two treatment regimens is essential since captopril is a continuous-use medication. Thus, this study explored the role of the transient receptor potential vanilloid 1 (TRPV1) in the effects of captopril on rat airways using two treatment regimens. Airway resistance, bronchoalveolar lavage (BAL), and histological and immunohistochemical analyses were conducted in rats administered with single or repeated doses of captopril. This study showed that the hyperresponsiveness to bradykinin and capsaicin in captopril-treated rats was acute. Treatment with the selective B2 antagonist, HOE140 reduced bradykinin hyperresponsiveness and abolished capsaicin exacerbation in single-dose captopril-treated rats. Likewise, degeneration of TRPV1-positive neurones also reduced hyperresponsiveness to bradykinin. Single-dose captopril treatment increased leukocyte infiltration in the BAL when compared with the vehicle and this increase was reduced by TRPV1-positive neurone degeneration. However, when compared with the vehicle treatment, animals treated with repeated doses of captopril showed an increase in leukocyte influx as early as 1 h after the last captopril treatment, but this effect disappeared after 24 h. Additionally, an increase in TRPV1 expression occurred only in animals who received repeated captopril doses and the degeneration of TRPV1-positive neurones attenuated TRPV1 upregulation. In conclusion, these data strongly indicate that a treatment regimen involving multiple doses of captopril not only enhances sensitisation but also upregulates TRPV1 expression. Consequently, targeting TRPV1 could serve as a promising strategy to reduce the negative impact of captopril on the airways.
ABSTRACT
Previous studies have shown that all kinin system is constitutively expressed in the normal and inflamed skin, with a potential role in both physiological and pathological processes. However, the understanding regarding the involvement of the kinin system in skin pigmentation and pigmentation disorders remains incomplete. In this context, the present study was designed to determine the role of kinins in the Monobenzone (MBZ)-induced vitiligo-like model. Our findings showed that MBZ induces higher local skin depigmentation in kinin receptors knockout mice (KOB1R, KOB2R and KOB1B2R) than in wild type (WT). Remarkably, lower levels of melanin content and reduced ROS generation were detected in KOB1R and KOB2R mice treated with MBZ. In addition, both KOB1R and KOB2R show increased dermal cell infiltrate in vitiligo-like skin, when compared to WT-MBZ. Additionally, lack of B1R was associated with greater skin accumulation of IL-4, IL-6, and IL-17 by MBZ, while KOB1B2R presented lower levels of TNF and IL-1. Of note, the absence of both kinin B1 and B2 receptors demonstrates a protective effect by preventing the increase in polymorphonuclear and mononuclear cell infiltrations, as well as inflammatory cytokine levels induced by MBZ. In addition, in vitro assays confirm that B1R and B2R agonists increase intracellular melanin synthesis, while bradykinin significantly enhanced extracellular melanin levels and proliferation of B16F10 cells. Our findings highlight that the lack of kinin receptors caused more severe depigmentation in the skin, as well as genetic deletion of both B1/B2 receptors seems to be linked with changes in levels of constitutive melanin levels, suggesting the involvement of kinin system in crucial skin pigmentation pathways.
Subject(s)
Melanins , Skin Pigmentation , Animals , Skin Pigmentation/drug effects , Mice , Melanins/metabolism , Melanins/biosynthesis , Mice, Knockout , Receptor, Bradykinin B1/metabolism , Receptor, Bradykinin B1/genetics , Cytokines/metabolism , Vitiligo/metabolism , Vitiligo/pathology , Receptor, Bradykinin B2/metabolism , Skin/metabolism , Skin/drug effects , Skin/pathology , Reactive Oxygen Species/metabolism , Mice, Inbred C57BL , Humans , MaleABSTRACT
Previous studies have demonstrated the role of γ-aminobutyric acid type B (GABAB) receptors in skin-related conditions and pain. However, most studies have focused on the main effects of GABAB on the central nervous system. Therefore, this study has aimed to determine the potential topical anti-inflammatory and anti-proliferative effects of baclofen cream in an inflammatory skin disease model. The effects of the baclofen cream were evaluated using acute and chronic models of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mouse ears. Histological and immunohistochemical evaluations were performed using an ear oedema assay. The effect of baclofen on keratinocyte proliferation was assessed in PAM212, the murine keratinocyte cell line. The results demonstrate that a single topical application of 5% baclofen, 7.5% baclofen, and 1% dexamethasone each inhibited acute TPA-induced ear oedema (58.94 ± 6.14%, 47.73 ± 11.26%, and 87.33 ± 4.59%, respectively). These results were confirmed by histological analysis. In the chronic model, baclofen (5%) and dexamethasone (1%) each inhibited ear oedema and the maximum inhibitory effect was reached at the end of the experiment (9th day of TPA application) with a percentage inhibition of 54.60 ± 6.15% for baclofen and 71.68 ± 3.45% for dexamethasone, when compared to the vehicle. These results were confirmed by histological analysis. Baclofen and dexamethasone also reduced proliferating cell nuclear antigen expression by 62.01 ± 6.65% and 70.42 ± 6.11%, respectively. However, baclofen did not inhibit keratinocyte proliferation in PAM212 cells. In conclusion, these results demonstrate that baclofen exhibits notable topical antiproliferative and anti-inflammatory properties and could be a potential therapeutic alternative for treating inflammatory and proliferative skin diseases.
Subject(s)
Dermatitis , Skin Diseases , Animals , Mice , Baclofen/pharmacology , Baclofen/therapeutic use , GABA-B Receptor Agonists/pharmacology , GABA-B Receptor Agonists/therapeutic use , Skin Diseases/drug therapy , Anti-Inflammatory Agents/adverse effects , Inflammation/drug therapy , Dexamethasone/therapeutic use , Edema/chemically induced , Edema/drug therapy , Edema/metabolism , Tetradecanoylphorbol Acetate/therapeutic useABSTRACT
Growing evidence indicates that transient receptor potential (TRP) channels contribute to different forms of pruritus. However, the endogenous mediators that cause itch through transient receptor potential channels signaling are poorly understood. In this study, we show that genetic deletion or pharmacological antagonism of TRPV4 attenuated itch in a mouse model of psoriasis induced by topical application of imiquimod. Human psoriatic lesions showed increased expression of several microRNAs, including the miR-203b-3p, which induced a calcium ion response in rodent dorsal root ganglion neurons and scratching behavior in mice through 5-HTR2B activation and the protein kinase Câdependent phosphorylation of TRPV4. Computer simulation revealed that the miR-203b-3p core sequence (GUUAAGAA) that causes 5-HTR2B/TRPV4-dependent itch targets the extracellular side of 5-HTR2B by interacting with a portion of the receptor pocket consistent with its activation. Overall, we reveal the unconventional pathophysiological role of an extracellular microRNA that can behave as an itch promoter through 5-HTR2B and TRPV4.
Subject(s)
MicroRNAs , Pruritus , Receptor, Serotonin, 5-HT2B , TRPV Cation Channels , Animals , Humans , Mice , Computer Simulation , Ganglia, Spinal , Mice, Inbred C57BL , MicroRNAs/genetics , MicroRNAs/metabolism , Pruritus/chemically induced , Pruritus/genetics , Pruritus/metabolism , TRPV Cation Channels/genetics , TRPV Cation Channels/metabolism , Receptor, Serotonin, 5-HT2B/genetics , Receptor, Serotonin, 5-HT2B/metabolismABSTRACT
Dry cough has been reported in patients receiving statin therapy. However, the underlying mechanism or other possible alterations in the airways induced by statins remain unknown. Thus, the aim of this study was to evaluate whether simvastatin promotes alterations in airways, such as bronchoconstriction and plasma extravasation, as well as the mechanism involved in these events. Using methods to detect alterations in airway resistance and plasma extravasation, we demonstrated that simvastatin [20 mg/kg, intravenous (i.v.)] caused plasma extravasation in the trachea (79.8 + 14.8 µg/g/tissue) and bronchi (73.3 + 8.8 µg/g/tissue) of rats, compared to the vehicle (34.2 + 3.6 µg/g/tissue and 29.3 + 5.3 µg/g/tissue, respectively). NG-nitro-L-arginine methyl ester (L-NAME, 30 mg/kg, intraperitoneal), a nitric oxide (NO) synthase inhibitor, Icatibant [HOE 140, 10 nmol/50 µl, intratracheal (i.t.)], a bradykinin B2 antagonist, and capsazepine (100 nmol/50 µl, i.t.), a TRPV1 antagonist, attenuated simvastatin-induced plasma extravasation. Simvastatin (5, 10 and 20 mg/kg) did not cause bronchoconstriction per se, but exacerbated the bronchoconstrictive response to bradykinin (30 nmol/kg, i.v.), a B2 agonist (0.7 + 0.1 ml/H2O), or capsaicin (30 nmol/kg, i.v.), a TRPV1 agonist (0.8 + 0.1 ml/H2O), compared to the vehicle (0.1 + 0.04 ml/H2O and 0.04 + 0.01 ml/H2O, respectively). The bronchoconstriction elicited by bradykinin (100 nmol/kg, i.v.) in simvastatin non-treated rats was inhibited by L-NAME. The exacerbation of bronchoconstriction induced by bradykinin or capsaicin in simvastatin-treated rats was inhibited by L-NAME, HOE 140 or capsazepine. These results suggest that treatment with simvastatin promotes the release of bradykinin, which, via B2 receptors, releases NO that can then activate the TRPV1 to promote plasma extravasation and bronchoconstriction.
Subject(s)
Bronchi/drug effects , Nitric Oxide/metabolism , Receptor, Bradykinin B2/metabolism , Simvastatin/adverse effects , TRPV Cation Channels/metabolism , Trachea/drug effects , Administration, Intravenous , Airway Resistance/drug effects , Animals , Bradykinin/administration & dosage , Bradykinin/analogs & derivatives , Bradykinin/pharmacology , Bradykinin B2 Receptor Antagonists/administration & dosage , Bradykinin B2 Receptor Antagonists/pharmacology , Bronchi/metabolism , Bronchoconstriction/drug effects , Capillary Permeability/drug effects , Capsaicin/administration & dosage , Capsaicin/analogs & derivatives , Capsaicin/pharmacology , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Injections, Intraperitoneal , Male , NG-Nitroarginine Methyl Ester/administration & dosage , NG-Nitroarginine Methyl Ester/pharmacology , Rats, Wistar , Simvastatin/administration & dosage , TRPV Cation Channels/antagonists & inhibitors , Trachea/metabolismABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Baccharis dracunculifolia (Asteraceae) is a commonly used plant in traditional medicine known as "alecrim-do-campo". Popularly it has been used as an immunostimulant, antibiotic, anti-inflammatory among other applications. So far, only a few studies have investigated the B. dracunculifolia anti-inflammatory effect and none has investigated the effectiveness of essential oil on skin diseases. AIM OF THE STUDY: The study aimed at evaluating the topical anti-inflammatory activity of B. dracunculifolia essential oil (BdEO) in mice models of acute and chronic skin inflammation. MATERIALS AND METHODS: BdEO was obtained from leaves and it was analyzed with Gas Chromatograph. Topical anti-inflammatory activity of BdEO (0.1, 0.3 and 1.0 mg/ear) was evaluated in Arachidonic Acid or TPA-induced acute and chronic skin inflammation in mice. Parameters such edema, cell migration and keratinocytes proliferation were evaluated. In addition, safety and a possible mechanism of action for BdEO essential oil were also investigated. RESULTS: Our results indicate that mainly terpenoids compounds compose BdEO. In addition, topical treatment with BdEO inhibited inflammatory parameters in both acute and chronic models of skin inflammation. This protective effect was associated with reduced edema formation, smaller cellular influx into the inflamed tissue and reduction of keratinocytes hyperproliferation. Although BdEO appears to exert its anti-inflammatory effect through a corticosteroid pathway, no local or systemic side effects were observed. CONCLUSION: Taken together, the present results showed that the essential oil obtained by hydrodistillation from B. dracunculifolia leaf samples exhibit remarkable topical anti-inflammatory properties. Therefore, our study demonstrated evidence for BdEO topical anti-inflammatory efficacy and safety, suggesting that it could be considered for developing of a new phytotherapeutic formulation as treatment for skin diseases.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Baccharis/chemistry , Drug Eruptions/drug therapy , Oils, Volatile/pharmacology , Animals , Anti-Inflammatory Agents/chemistry , Drug Eruptions/pathology , Edema/chemically induced , Edema/drug therapy , Epidermis/pathology , Female , Lymphatic System/drug effects , Mice , Oils, Volatile/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Receptors, Glucocorticoid/metabolismABSTRACT
BACKGROUND AND PURPOSE: The entire kallikrein-kinin system is present in the skin, and it is thought to exert a relevant role in cutaneous diseases, including psoriasis. The present study was designed to evaluate the relevance of kinin receptors in the development and progression of a model of psoriasis in mice. EXPERIMENTAL APPROACH: The effects of kinin B1 and B2 receptor knockout and of kinin receptor antagonists (SSR240612C or FR173657) were assessed in a model of psoriasis induced by imiquimod in C57BL/6 mice. Severity of psoriasis was assessed by histological and immunohistochemical assays of skin, along with objective scores based on the clinical psoriasis area and severity index. KEY RESULTS: Both kinin receptors were up-regulated following 6 days of imiquimod treatment. Kinin B1 and B2 receptor deficiency and the use of selective antagonists show morphological and histological improvement of the psoriasis hallmarks. This protective effect was associated with a decrease in undifferentiated and proliferating keratinocytes, decreased cellularity (neutrophils, macrophages, and CD4+ T lymphocytes), reduced γδ T cells, and lower accumulation of IL-17. The lack of B2 receptors resulted in reduced CD8+ T cells in the psoriatic skin. Relevantly, blocking kinin receptors reflected the improvement of psoriasis disease in the well-being behaviour of the mice. CONCLUSIONS AND IMPLICATIONS: Kinins exerted critical roles in imiquimod-induced psoriasis. Both B1 and B2 kinin receptors exacerbated the disease, influencing keratinocyte proliferation and immunopathology. Antagonists of one or even both kinin receptors might constitute a new strategy for the clinical treatment of psoriasis.
Subject(s)
Kinins , Psoriasis , Animals , CD8-Positive T-Lymphocytes , Mice , Mice, Inbred C57BL , Psoriasis/drug therapy , Receptor, Bradykinin B1 , Receptor, Bradykinin B2ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Popularly used in India and sub-Hymalaian region, Moringa oleifera (Moringaceae) is associated with healing properties demonstrated in its use as treatment of acute and chronic skin diseases. Our study aimed at investigating the effects of M. oleifera seed oil (MOSO) in animal models for inflammatory and hyperproliferative skin conditions. MATERIALS AND METHODS: MOSO was analyzed using gas chromatography/mass spectrometry. The anti-inflammatory and anti-hyperproliferative effects of treatment with either MOSO or oleic acid (OA), its main constituent, was evaluated. Acute and chronic inflammation was induced by applying 12-O-Tetradecanoylphorbol-13-acetate (TPA) and acute inflammation with either Arachidonic Acid (AA) or Phenol onto the ear of Swiss mice. Systemic activity and the influence of glucocorticoid receptors (GC) was also evaluated. RESULTS: Topical application of MOSO and OA inhibited ear edema caused by TPA, and Phenol. Only MOSO inhibited ear edema induced by AA. Neutrophil migration was also inhibited by treatment with MOSO. Topical application of MOSO, but not OA, significantly reduced chronic skin inflammation and epidermal hypertrophy induced by multiple TPA applications. Pre-treatment with GC antagonist mifepristone reversed the anti-inflammatory effect of MOSO and OA on the TPA model. Repeated administration of MOSO show a similar effect to dexamethasone on thymus weight, though MOSO did not present any influence on skin thickness, as well as in the weight of the spleen, adrenal gland and lymph node. CONCLUSION: The results suggest that MOSO is effective as a treatment for skin diseases that rely on keratinocyte hyperproliferation. OA is also effective in acute inflammation. Both MOSO and OA depend on GC activation for anti-inflammatory effect but do not exhibit the same adverse effects seen in topical treatment with dexamethasone. We hereby evidence the use of MOSO as a topical anti-inflammatory agent in inflammatory skin diseases, thus, expanding its therapeutic potential.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dermatitis, Contact/drug therapy , Moringa oleifera , Oleic Acid/therapeutic use , Plant Oils/therapeutic use , Adrenal Glands/drug effects , Animals , Atrophy/drug therapy , Atrophy/metabolism , Cell Proliferation/drug effects , Dermatitis, Contact/metabolism , Edema/drug therapy , Edema/metabolism , Female , Irritants , Keratinocytes/drug effects , Lymph Nodes/drug effects , Mice , Receptors, Glucocorticoid/metabolism , Seeds , Skin/drug effects , Skin/pathology , Spleen/drug effects , Tetradecanoylphorbol Acetate , Thymus Gland/drug effectsABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Cyperus rotundus L. (Cyperaceae) is considered one of the most widely distributed plant species in the world, especially in tropical and subtropical regions. In addition, it is commonly used in India, China and Japan in traditional medicine to treat different diseases, including dermatitis and other skin disorders. AIM OF THE STUDY: To investigate the topical anti-inflammatory activity of C. rotundus rhizome ethanolic extract in models of acute and chronic dermatitis. MATERIALS AND METHODS: Phytochemical analysis was carried out using High-performance liquid chromatography-ultraviolet detection (HPLC/UV) to determine the presence of quercetin and chlorogenic acid in C. rotundus extract. Topical anti-inflammmatory effects of C. rotundus extract were evaluated on arachidonic acid (AA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice. Skin biopsies were collected and submitted to histological and enzymatic analysis to evaluate the C. rotundus effect in leukocyte migration into inflamed tissue. Antiproliferative activity of C. rotundus was confirmed by PCNA immunostained cell analysis. Systemic and possible adverse effects of topical treatment with C. rotundus were evaluated by the skin atrophy and same organ weights. In addition, the glucocorticoid receptor (GR) antagonist mifepristone was used to investigate possible GR-mediated mechanisms of action. RESULTS: The phytochemical analysis show that C. rotundus ethanol extract contains 45 µg/g of chlorogenic acid. Topical treatment with C. rotundus extract reduced ear edema and cellular infiltrate in acute and chronic skin inflammation models. Moreover, mice topically treated with C. rotundus exhibited decrease in TPA-induced keratinocyte hyperproliferation. Relevantly, topical treatment with C. rotundus did not caused skin atrophy or changes in lymphoid organ weight. The anti-inflammatory effect of C. rotundus was not influenced by the GR antagonist. CONCLUSION: The results here demonstrate for the first time the topical anti-inflammatory and antiproliferative efficacy of C. rotundus extract, suggesting that the extract could be a potential new therapeutic tool for the treatment of inflammatory skin disorders.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cyperus , Dermatitis, Contact/drug therapy , Plant Extracts/therapeutic use , Adrenal Glands/drug effects , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Arachidonic Acid , Atrophy/drug therapy , Cell Proliferation/drug effects , Edema/drug therapy , Edema/metabolism , Female , Irritants , Keratinocytes/drug effects , Lymph Nodes/drug effects , Mice , Phytochemicals/analysis , Phytochemicals/therapeutic use , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rhizome , Skin/drug effects , Skin/pathology , Spleen/drug effects , Tetradecanoylphorbol Acetate , Thymus Gland/drug effectsABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Vochysia bifalcata is a Brazilian native tree commonly used for economic purpose in the reforestation and in the manufacture of products. However, the potential usage of other parts of the plant is usually wasted. Besides, other species of Vochysia are well known for its anti-inflammatory action. AIM OF THE STUDY: In this study we evaluate the possible anti-inflammatory activity of the hydroethanolic extract from the leaves of V. bifalcata in models of mice skin inflammation. MATERIALS AND METHODS: Effects of V. bifalcata were evaluated in croton oil-induced acute and chronic skin inflammation. The role of glucocorticoid receptors in the extract effect was assessed by using a glucocorticoid receptor antagonist and by a specific binding assay. Possible adverse effects were evaluated after multiple treatments with the extract in a skin atrophy model. RESULTS: Topical application of V. bifalcata reduced ear edema formation, cell infiltration and interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels. In the chronic model, besides edema formation and cell infiltration, the extract inhibited epidermal hyperproliferation and Proliferating Cell Nuclear Antigen expression. V. bifalcata seems to act by biding to corticoid receptors, however it did not induce corticoid related undesirable effects. CONCLUSION: Hydroethanolic extract from leaves of V. bifalcata could be an interesting tool in the search for new anti-inflammatory and antiproliferative agents for the treatment of skin disorders.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dermatitis, Contact/drug therapy , Edema/drug therapy , Myrtales , Plant Extracts/therapeutic use , Adrenal Cortex Hormones , Animals , Atrophy/drug therapy , Cell Line , Croton Oil , Edema/chemically induced , Edema/immunology , Female , Humans , Interleukin-6/immunology , Mice , Phytotherapy , Plant Leaves , Receptors, Glucocorticoid/metabolism , Skin/drug effects , Skin/pathology , Tetradecanoylphorbol Acetate , Treatment Outcome , Tumor Necrosis Factor-alpha/immunologyABSTRACT
Contact dermatitis is a very common inflammatory reaction in the skin, causing not only aesthetic problems but also loss functionality at work. The molecular mechanisms of contact dermatitis induced by chemical irritants are still unclear. Considering that transient receptor potential channels (TRP) may induce neurogenic inflammation and the exacerbation of inflammatory responses, here we investigated the role of transient receptor potential channel ankyrin type-1 (TRPA1) in skin inflammation evoked by chemical irritants. Ear oedema and nociceptive responses elicited by the topical application of xylene and toluene were measured in Swiss mice, wild type and TRPA1 knockout (Trpa1-/-) C57BL/6 mice. Histological analyses were performed in mice subjected to the ear oedema assay. Topical application of xylene and toluene in the mouse ear induced an edematogenic response (0.113⯱â¯0.008â¯mm and 0.067⯱â¯0.011â¯mm), compared to vehicle (0.008⯱â¯0.008â¯mm), assessed by ear thickness measurements and histological analyses. These responses were prevented by topical pretreatment with a selective TRPA1 antagonist, HC-030031 (% inhibition: xylene 36.8⯱â¯9.4% and toluene 50.7⯱â¯11.0%), and by the genetic deletion of TRPA1 ((% inhibition: xylene 66.6⯱â¯16.7% and toluene 75⯱â¯0%). In addition, the topical application of xylene and toluene to the mouse paw elicited nociceptive responses, which were significantly reduced by oral treatment with HC-030031 ((% of inhibition: 84.9⯱â¯1.3% and 27.1⯱â¯8.0%, respectively); nociceptive responses were almost completely abolished in Trpa1-/-mice. Our data suggest that the activation of TRPA1 could be involved in some of the symptoms of irritant-mediated contact dermatitis, such as oedema, pain and neurogenic inflammation.
Subject(s)
Skin/drug effects , TRPA1 Cation Channel/metabolism , Toluene/pharmacology , Xylenes/pharmacology , Animals , Edema/chemically induced , Edema/genetics , Edema/metabolism , Edema/pathology , Gene Knockout Techniques , Inflammation/chemically induced , Inflammation/metabolism , Mice , Mice, Inbred C57BL , Nociception/drug effects , TRPA1 Cation Channel/antagonists & inhibitors , TRPA1 Cation Channel/deficiency , TRPA1 Cation Channel/genetics , VolatilizationABSTRACT
Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes related to psoriasis pathogenesis, such as inflammation and cell proliferation. The aim of this study was to investigate the influence of renin inhibition on inflammation parameters and keratinocyte proliferation in a mouse model of chronic skin inflammation induced by croton oil. Aliskiren had anti-inflammatory effects by reducing levels of tumor necrosis factor-α and interleukin -6, and by inhibiting myeloperoxidase activity. Aliskiren also showed antiproliferative activity by reducing epidermal hyperplasia and proliferating cell nuclear antigen levels. Aliskiren treatment did not induce alterations in the cardiovascular system, normal skin thickness, and organ weight. These results suggest that aliskiren could be a valuable tool to be incorporated in the treatment of hyperproliferative and inflammatory skin disorders such as psoriasis.
Subject(s)
Amides/pharmacology , Antihypertensive Agents/pharmacology , Fumarates/pharmacology , Skin Diseases/drug therapy , Angiotensin II/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Cardiovascular System/drug effects , Cardiovascular System/metabolism , Disease Models, Animal , Female , Inflammation/drug therapy , Inflammation/metabolism , Keratinocytes/drug effects , Keratinocytes/metabolism , Mice , Psoriasis/drug therapy , Psoriasis/metabolism , Renin/metabolism , Renin-Angiotensin System/drug effects , Skin Diseases/metabolismSubject(s)
Edema/etiology , Inflammation/etiology , Periodontitis/complications , Receptor, Bradykinin B1/immunology , Alveolar Bone Loss/etiology , Alveolar Bone Loss/immunology , Alveolar Bone Loss/pathology , Animals , Chondrus , Disease Models, Animal , Edema/chemically induced , Edema/immunology , Edema/pathology , Extremities/pathology , Inflammation/immunology , Inflammation/pathology , Interleukin-1beta/immunology , Male , Periodontitis/immunology , Periodontitis/pathology , Rats , Rats, Wistar , Receptor, Bradykinin B1/analysis , Tumor Necrosis Factor-alpha/immunologyABSTRACT
The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline and other databases were searched. Heterogeneity was explored through I2 associated with a p-value. Of 739 identified publications, 25 were included in the meta-analysis. The global evaluation of Cochrane resulted in 19 studies with a high level of bias and six with unclear risk. Due to the lack of information in primary studies, direct meta-analyses were conducted only for amfepramone and mazindol. Compared to placebo, amfepramone resulted in higher weight loss in the short-term (<180 days; mean difference (MD) -1.281 kg; p<0.05; I2: 0.0%; p=0.379) and long-term (≥180 days; MD -6.518 kg; p<0.05; I2: 0.0%; p=0.719). Only studies with long-term follow up reported efficacy in terms of abdominal circumference and 5-10% weight reduction. These results corroborated the finding that the efficacy of amfepramone is greater than that of placebo. Treatment with mazindol showed greater short-term weight loss than that with placebo (MD -1.721 kg; p<0.05; I2: 0.9%; p=0.388). However, metabolic outcomes were poorly described, preventing a meta-analysis. A mixed treatment comparison corroborated the direct meta-analysis. Considering the high level of risk of bias and the absence of important published outcomes for anti-obesity therapy assessments, this study found that the evaluated drugs showed poor evidence of efficacy in the treatment of overweight and obese patients. Robust safety data were not identified to suggest changes in their regulatory status.
Subject(s)
Appetite Depressants/therapeutic use , Diethylpropion/therapeutic use , Mazindol/therapeutic use , Obesity/drug therapy , Overweight/drug therapy , Appetite Depressants/metabolism , Diethylpropion/metabolism , Humans , Mazindol/metabolism , Obesity/metabolism , Overweight/metabolism , Publication Bias , Reproducibility of Results , Risk Factors , Treatment Outcome , Weight Loss/drug effectsABSTRACT
Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitária) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.
Subject(s)
Appetite Depressants/therapeutic use , Diethylpropion/therapeutic use , Mazindol/therapeutic use , Obesity/drug therapy , Amphetamines/therapeutic use , Brazil , Cyclobutanes/therapeutic use , Drug Approval , Humans , Risk Assessment/trends , Treatment OutcomeABSTRACT
The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline and other databases were searched. Heterogeneity was explored through I2 associated with a p-value. Of 739 identified publications, 25 were included in the meta-analysis. The global evaluation of Cochrane resulted in 19 studies with a high level of bias and six with unclear risk. Due to the lack of information in primary studies, direct meta-analyses were conducted only for amfepramone and mazindol. Compared to placebo, amfepramone resulted in higher weight loss in the short-term (<180 days; mean difference (MD) -1.281 kg; p<0.05; I2: 0.0%; p=0.379) and long-term (≥180 days; MD -6.518 kg; p<0.05; I2: 0.0%; p=0.719). Only studies with long-term follow up reported efficacy in terms of abdominal circumference and 5-10% weight reduction. These results corroborated the finding that the efficacy of amfepramone is greater than that of placebo. Treatment with mazindol showed greater short-term weight loss than that with placebo (MD -1.721 kg; p<0.05; I2: 0.9%; p=0.388). However, metabolic outcomes were poorly described, preventing a meta-analysis. A mixed treatment comparison corroborated the direct meta-analysis. Considering the high level of risk of bias and the absence of important published outcomes for anti-obesity therapy assessments, this study found that the evaluated drugs showed poor evidence of efficacy in the treatment of overweight and obese patients. Robust safety data were not identified to suggest changes in their regulatory status.
Subject(s)
Humans , Appetite Depressants/therapeutic use , Diethylpropion/therapeutic use , Mazindol/therapeutic use , Obesity/drug therapy , Overweight/drug therapy , Appetite Depressants/metabolism , Diethylpropion/metabolism , Mazindol/metabolism , Obesity/metabolism , Overweight/metabolism , Publication Bias , Reproducibility of Results , Risk Factors , Treatment Outcome , Weight Loss/drug effectsABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: 3ß,6ß,16ß-Trihydroxylup-20(29)-ene (TTHL) is a triterpene isolated from the flowers of Combretum leprosum, a plant used in folk medicine in the north of Brazil for the treatment of skin disorders. AIM OF THE STUDY: In the present study, TTHL was evaluated as a potential topical anti-inflammatory and anti-proliferative agent through in vivo and in vitro models. MATERIAL AND METHODS: Anti-inflammmatory and anti-proliferative effects of TTHL were assessed using Swiss mice in acute and chronic models of skin inflammation induced by 12-O-tetradecanoylphorbol-acetate (TPA) application. Anti-proliferative activity was proved through in vitro experiments with the HaCaT human keratinocyte cell line. RESULTS: Treatment with TTHL inhibited inflammatory parameters such as oedema formation and cellular infiltration in acute and chronic models. In the chronic model, TTHL also inhibited epidermal hyperproliferation, as evidenced by reduction of epidermis thickness and proliferating cell nuclear antigen expression. The anti-proliferative effect was confirmed by the capability of TTHL in reducing the proliferation and inducing cell apoptosis of HaCaT cells. Suggesting a mechanism of action, TTHL showed activation of corticosteroid receptors, but without the induction of corticosteroid-related cutaneous side effects. CONCLUSION: Our results demonstrate consistent anti-inflammatory and anti-proliferative activity and assign TTHL as a valuable tool in the development of a new treatment for skin inflammatory and proliferative diseases, such as psoriasis.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Dermatitis, Contact/prevention & control , Keratinocytes/drug effects , Psoriasis/prevention & control , Skin/drug effects , Triterpenes/pharmacology , Animals , Apoptosis/drug effects , Cell Line , Chronic Disease , Dermatitis, Contact/etiology , Dermatitis, Contact/metabolism , Dermatitis, Contact/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Edema/chemically induced , Edema/prevention & control , Female , Hormone Antagonists/pharmacology , Humans , Keratinocytes/metabolism , Keratinocytes/pathology , Mice , Mifepristone/pharmacology , Proliferating Cell Nuclear Antigen/metabolism , Psoriasis/chemically induced , Psoriasis/metabolism , Psoriasis/pathology , Receptors, Glucocorticoid/drug effects , Receptors, Glucocorticoid/metabolism , Skin/metabolism , Skin/pathology , Tetradecanoylphorbol Acetate , Time FactorsABSTRACT
Evidências recentes apontam a psoríase como possível fator sistêmico capaz de interferir no desenvolvimento, progressão e severidade da doença periodontal. Por outro lado, o quadro infeccioso presente na doença periodontal pode atuar como fator de risco para o desenvolvimento da psoríase ou como fator desencadeador da exacerbação de lesões cutâneas em remissão. Este estudo buscou discutir os dados presentes na literatura científica a respeito da relação entre psoríase e doença periodontal e apresentar os possíveis mecanismos biológicos que poderiam sustentar esta associação. Foram selecionados 10 estudos clínicos observacionais, publicados até dezembro de 2016, que avaliaram a relação entre psoríase e doença periodontal. Uma sequência de estudos observacionais demonstra uma relação bidirecional entre a psoríase e doença periodontal, porém sem ainda poder estabelecer uma relação de causalidade entre elas que possa designar uma doença como comorbidade da outra. É evidente a necessidade de mais estudos, especialmente para evidenciar se esta relação realmente acontece de maneira causal, ou se ela ocorre indiretamente devido a presença de outros fatores envolvidos, como o impacto nos hábitos de vida do paciente com psoríase e a presença de fatores de risco genéticos e ambientais em comum nas duas patologias. (AU)
Recent evidence demonstrates psoriasis as a possible systemic factor that could affect the development, progression and severity of periodontal disease. Furthermore, the infections present in periodontal disease may act as a risk factor for psoriasis development or as a triggering factor in exacerbation of cutaneous lesions in remission. This study aimed to discuss the date found in scientific literature regarding the relation between psoriasis and periodontal disease and to present the possible biological mechanisms that could explain this association. There were selected 10 observational clinical studies published until December 2016 that evaluate the relation between psoriasis and periodontal disease. A sequence of observational studies demonstrates a bidirectional relation between psoriasis and periodontal disease, but without establish a causal relation between theythat could determine a disease as a comorbidity of another. The needs for more studies is evident, especially to evidence if the relation really happens in a causal way, or if it occurs indirectly due other factors involved, such as impact of psoriatic patient's life habits and the presence of genetic and ambient risk factors shared byboth pathologies. (AU)
Subject(s)
Periodontal Diseases , Psoriasis , Comorbidity , Risk Factors , InflammationABSTRACT
BACKGROUND: Ethnobotanical studies of the Sapium genus reveal that many species are widely used in several countries as therapeutic drugs and they are widely used in folk medicine for treatment of different diseases, including skin inflammation. This raises interest in the study of the pharmacological properties and phytochemical composition of these plants. The biological properties of Sapium glandulatum, a native species of southern Brazil, has not been reported in the literature. PURPOSE: The aim of the present study was to investigate the anti-inflammatory action of the hydroalcoholic extract of Sapium glandulatum (EHSG) leaves in mouse models of acute or chronic skin inflammation. STUDY DESIGN/METHODS: Topical effects of EHSG were evaluated in 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced edema in the ear. Systemic effects of the extract were studied in a TPA-induced ear edema model, as well as in a carrageenan-induced paw edema model. To gain insight into the mechanism by which EHSG blocked inflammation, we evaluated the role of glucocorticoid receptors (GR) using the TPA-induced ear edema model and also measured specific binding in a glucocorticoid assay. Possible adverse effects of EHSG were evaluated after multiple treatments with the extract in the skin atrophy model on the ear and with the alkaline comet assay. RESULTS: EHSG presented potent anti-inflammatory activity when applied topically in acute and chronic models, inhibiting edema formation and leukocyte migration as well as expression pro-inflammatory cytokines IL-1ß, IL-6 and TNF-α in the tissue. Similar anti-inflammatory effects were found following oral treatment in both ear and paw edema models. Strikingly, the EHSG-induced blockade of leukocyte migration was reversed by mifepristone, a GR antagonist. Additionally, a specific binding assay revealed that ESGH interacts with GR. Multiple treatments with EHSG failed to induce adverse effects when evaluated in the skin atrophy model and bone marrow genotoxicity test. CONCLUSION: Taken together, our data suggest that EHSG is a potential source of anti-inflammatory tool compounds for the treatment of pro-inflammatory-derived skin diseases, and its mechanism of action may be, at least in part, via the GR pathway.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Plant Extracts/pharmacology , Receptors, Glucocorticoid/metabolism , Sapium/chemistry , Administration, Oral , Administration, Topical , Animals , Brazil , Carrageenan/toxicity , Cytokines/metabolism , Drug Evaluation, Preclinical/methods , Edema/chemically induced , Edema/drug therapy , Male , Mice , Plant Extracts/administration & dosage , Plant Leaves/chemistry , Plants, Medicinal/chemistry , Tetradecanoylphorbol Acetate/toxicityABSTRACT
Angiotensin-converting enzyme inhibitors (ACEIs) are widely used in the treatment of hypertension, congestive heart failure and renal disease, and are considered relatively safe and generally well-tolerated drugs. However, adverse effects of ACEIs have been reported, including non-productive cough and angioedema, which can lead to poor adherence to therapy. The mechanisms by which ACEIs promote adverse effects are not fully elucidated, although increased bradykinin plasma levels following ACEI therapy seem to play an important role. Since bradykinin can sensitise the transient potential vanilloid receptor 1 (TRPV1), we investigated the role of TRPV1 in plasma extravasation in the trachea and bronchi of rats treated with the ACEI captopril. We observed that intravenous (i.v.) administration of captopril did not cause plasma extravasation in the trachea or bronchi of spontaneously breathing rats, but induced plasma extravasation in the trachea and bronchi of artificially ventilated rats. The intratracheal (i.t.) instillation of capsaicin or bradykinin also induced an increase in plasma extravasation in the trachea and bronchi of artificially ventilated rats. As expected, capsaicin-induced plasma extravasation was inhibited by i.t. pretreatment with the TRPV1 selective antagonist capsazepine (CPZ) while bradykinin-induced plasma extravasation was reduced by i.t. pretreatment with the selective B2 receptor antagonist Icatibant, originally known as HOE 140 (HOE). Interestingly, bradykinin-induced plasma extravasation was also inhibited by CPZ. The pretreatment with HOE and CPZ, singly or in combination and at doses which do not cause inhibitory effects per se, significantly inhibited the plasma extravasation induced by captopril treatment in artificially ventilated rats. In addition, treatment with a high dose of capsaicin in newborn rats, which induces degeneration of TRPV1-expressing sensory neurons, abolished both capsaicin and captopril-induced plasma extravasation in artificially ventilated rats. In conclusion, our study identified that captopril treatment promoted sensitisation of TRPV1, via B2 receptor activation, inducing plasma extravasation in the airways of mechanically ventilated rats. The present findings add a new view about the role of TRPV1 in the plasma extravasation induced by captopril and could to contribute to the elucidation of mechanisms by which ACEI induces adverse effects on airways.